What happened with AMGN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Amgen is a biotechnology company that discovers, develops and supplies medicines for patients, with products including Prolia, Repatha, Otezla and ENBREL. Medicine sales provide the great majority of its revenue, and the United States is its largest market. In the U.S., wholesalers buy its medicines and distribute them to clinics, hospitals and pharmacies. McKesson, Cencora and Cardinal Health together account for most of Amgen’s worldwide revenue, making these three customers central to its business.
Wholesalers are the direct buyers, but government healthcare programs and private insurers determine much of the coverage and reimbursement that supports demand. Insurers and pharmacy benefit managers—the organizations that manage prescription-drug benefits—can restrict access and demand rebates in exchange for covering medicines. Mandatory government discounts and Medicare price setting also limit what Amgen receives, including for ENBREL.
Amgen must obtain and maintain regulatory approval to sell its medicines. Its business also depends on patent protection and reliable manufacturing, with most commercial production concentrated in Puerto Rico. Prolia and XGEVA already face competing versions of their biological medicines, known as biosimilars, following patent expirations.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Watch UCB for Amgen’s exposure to osteoporosis-treatment demand through EVENITY: the two share its worldwide development costs and commercialization profits and losses equally.
Regeneron competes for the same treatment demand as Amgen: EYLEA faces PAVBLU in retinal disease, and Praluent faces Repatha in cholesterol lowering. Watch EYLEA sales and patent rulings for signs of the competition facing PAVBLU.
AbbVie’s Humira and Skyrizi compete for psoriasis patients treated by Amgen’s ENBREL and Otezla. Watch those medicines rather than AbbVie’s total sales when assessing competition for Amgen’s psoriasis business.
Amgen and AstraZeneca share exposure to severe-asthma demand through jointly developed TEZSPIRE: Amgen sells it in the United States, while AstraZeneca markets it elsewhere. AstraZeneca’s progress with TEZSPIRE shows how adoption is developing outside Amgen’s U.S. sales territory.
Eli Lilly’s obesity medicines compete for the future treatment demand Amgen seeks with its developing MariTide program. Lilly also sells Taltz, which competes with Amgen’s psoriasis medicines.
Novo Nordisk already sells obesity medicines in the market Amgen seeks to enter with MariTide, which remains in development. Its obesity business is therefore competition for Amgen’s future treatment opportunity, not an existing MariTide sales stream.
Novartis is both a rival and a sales partner for Amgen: Cosentyx and Leqvio compete in psoriasis and cholesterol lowering, while Novartis sells Amgen’s migraine-prevention medicine Aimovig outside the United States and Japan. Watch Aimovig demand in those partner markets separately from the competing medicines.
Sanofi’s Praluent competes with Amgen’s Repatha for cholesterol treatment, and their patent disputes can affect access to European markets. Watch rulings on Praluent and on specified Repatha uses in Belgium, France, Germany, Italy and the Netherlands, where injunctions are being sought.
Johnson & Johnson’s Janssen medicines compete for psoriasis and myeloma treatment demand served by Amgen’s ENBREL, Otezla and KYPROLIS. Those prescription-medicine businesses, rather than Johnson & Johnson as a whole, are the relevant competition for Amgen.
Bristol Myers Squibb’s Sotyktu competes directly with Amgen’s Otezla for patients seeking oral psoriasis treatment. Sotyktu’s sales are the line to watch for competition within this oral-treatment market.
Amgen depends on BeOne to sell XGEVA, BLINCYTO and KYPROLIS in China: BeOne buys the Amgen-manufactured medicines, and the companies share profits and losses equally during their product-specific commercialization periods. Watch Chinese sales of these three medicines, rather than BeOne’s overall growth, for the direct connection to Amgen.
Alvotech competes with Amgen’s biosimilar portfolio and seeks to market versions of Prolia and XGEVA; it makes medicines for partners that sell them and pay it supply and licensing revenue. Watch the patent case over its denosumab biosimilar application for developments affecting another potential competitor to these Amgen products.
Amneal Pharmaceuticals seeks to compete with three Amgen products by marketing a denosumab biosimilar to Prolia and XGEVA and a generic version of KYPROLIS. Watch the separate patent cases: Amgen is seeking to block the biosimilar and delay FDA approval of the KYPROLIS generic.
Dr. Reddy’s and Alvotech seek to sell a denosumab biosimilar competing with Amgen’s Prolia and XGEVA, adding potential competition as Amgen expects faster sales erosion from biosimilars. Their application faces Amgen’s patent suit, with no trial date set.
GSK’s Nucala competes with Amgen’s TEZSPIRE for severe-asthma patients who need biologic medicines. Nucala, rather than GSK’s broader vaccine or general-medicine sales, is the product to watch for this competition.
Ligand supplies Captisol for Amgen’s KYPROLIS and licenses the rights to use it, so Amgen pays Ligand for material and a royalty of 1.5%–3.0% of annual KYPROLIS net sales. Ligand’s KYPROLIS royalties provide a direct read on the sales base of this Amgen medicine.
Dr. Reddy's Laboratories Limited earningsRDY
If Dr. Reddy’s report updates its denosumab biosimilar application, it will show how close another potential competitor is to Amgen’s Prolia and XGEVA.
Look for concrete movement in the application or patent case; a report is not proof that the biosimilar has launched or taken sales. Progress with fewer legal hurdles would bring another competitor for Prolia and XGEVA closer. Continued legal or regulatory delays would mean no new pressure from this applicant yet, though other biosimilar competition remains.
Novartis AG earningsNVS
Novartis’s report can show whether Leqvio is gaining ground against Amgen’s Repatha in cholesterol treatment.
Watch Leqvio’s sales or adoption, not Novartis’s total sales against Amgen’s Repatha. Faster Leqvio growth would show that more patients or payers are accepting an alternative in the same treatment market, potentially making prescriptions and coverage harder for Repatha to win. Slower growth would be weaker evidence of pressure from Leqvio, not proof that Repatha demand is rising.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report can show whether Sotyktu is gaining sales against Amgen’s Otezla in oral psoriasis treatment.
Focus on Sotyktu’s own sales trend, not Bristol Myers Squibb’s overall results. Stronger sales would show a competing oral psoriasis treatment attracting patients and could add pressure on Otezla to win prescriptions and coverage. Weaker sales would mean less evidence of pressure from Sotyktu, but would not establish that Otezla is winning.
Ligand Pharmaceuticals Inc. earningsLGND
If Ligand reports KYPROLIS royalties separately, its report will offer a direct clue to sales of Amgen’s medicine.
If Ligand breaks out KYPROLIS royalties, compare that line with the same line in the prior period; its total royalties also come from other products. A rise would generally point to a larger sales base for Amgen’s medicine. A fall could reflect weaker sales, but contract timing can also affect the figure. Without a separate breakout, the total does not settle how KYPROLIS is doing.
Eli Lilly & Co. earningsLLY
Eli Lilly’s report can show how much demand its obesity medicines are drawing in the market Amgen hopes to enter with MariTide.
Watch sales of Lilly’s obesity medicines; they are not evidence of MariTide sales or effectiveness, since Amgen’s program remains in development. Continued growth would show established competitors attracting demand and raise the bar for MariTide if it reaches market. A slowdown would mean less momentum for Lilly, not a settled outlook for patient demand or MariTide.
AstraZeneca PLC earningsAZN
AstraZeneca’s report can show whether TEZSPIRE, which it markets outside the United States, is gaining adoption in those markets.
Focus on TEZSPIRE sales or adoption outside the United States, not Amgen’s U.S. sales. Growth there would show the jointly developed medicine is attracting patients beyond Amgen’s U.S. territory. Weak growth would point to slower adoption in those markets, but would not settle how TEZSPIRE is selling in the United States.
Amgen Inc earningsThis company
Amgen’s report will show whether revenue from selling more medicines can offset pressure from falling net prices.
Read product-sales volume alongside net selling price. Growing volume with steadier prices means Amgen is selling more without giving up much more per sale. If volume rises while net prices fall, discounts, rebates or the mix of medicines may be eating into that growth. The first pattern points to firmer sales growth; the second means Amgen must sell more just to protect revenue.
BeOne Medicines Ltd. earningsONC
BeOne Medicines’ report can show how Amgen’s XGEVA, BLINCYTO and KYPROLIS are selling in China.
Look for China sales of these three medicines, not BeOne Medicines’ overall growth; if the report does not break them out, total revenue cannot stand in for them. Growing sales would show a larger channel for Amgen-supplied medicines sold by BeOne, and a larger sales base for the applicable profit-sharing arrangements. Falling sales would mean a weaker contribution from this partner channel.
